OTCMKTS:NEXI NexImmune Q4 2023 Earnings Results & Report NexImmune reported Q4 2023 earnings on April 16, 2024. The company reported EPS of -$4.99. Research:Profile Earnings Announcement Details QuarterQ4 2023Report DateApril 16, 2024Conference Call8:00 AM ET NexImmune EPS ResultsActual EPS-$4.99Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersNexImmune Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsNexImmune's next earnings date is estimated for Tuesday, November 17, 2026, based on past reporting schedules. Conference Call ResourcesCompany Profile NexImmune Q4 2023 Earnings FAQ Did NexImmune beat earnings estimates for Q4 2023? NexImmune (OTCMKTS:NEXI) reported earnings of -$4.99 per share for Q4 2023. The report was announced on Tuesday, April 16, 2024. When is NexImmune's next earnings date? NexImmune's next earnings date is estimated for Tuesday, November 17, 2026. MarketBeat tracks confirmed and estimated earnings dates for NexImmune on the company's earnings history page. NexImmune Earnings HeadlinesItalian state investor CDP to raise stake in payments group NexiMay 25, 2026 | reuters.comShattuck Labs stock craters following pipeline and job cutsOctober 2, 2024 | msn.comMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.November 10 at 1:00 AM | Weiss Ratings (Ad)NexImmune moves forward with wind-down processAugust 31, 2024 | bizjournals.comNexImmune adjourns special meeting to explore optionsAugust 4, 2024 | investing.comNEXI Stock Alert: NexImmune Delists From NasdaqJuly 12, 2024 | investorplace.comSee More NexImmune Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like NexImmune? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NexImmune and other key companies, straight to your email. Email Address About NexImmuneNexImmune (OTCMKTS:NEXI) was a biotechnology company focused on developing cell-based immunotherapies for cancer. Its Artificial Immune Modulation (AIM) platform was designed to activate and expand T cells that recognize specific cancer-associated targets. The company’s investigational programs included NEXI-001, a T-cell therapy for acute myeloid leukemia, and NEXI-002, a program for multiple myeloma. NexImmune was based in Gaithersburg, Maryland, and its therapies were in clinical development rather than commercially available. NexImmune later discontinued operations and filed for Chapter 7 bankruptcy in 2023. Its programs should therefore be understood as historical development efforts, not as an indication of current commercial services.View NexImmune ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles D-Wave Quantum Has Long-Term Potential, But Is Now the Time to Buy?Archer Aviation's FAA Certificate Is a Milestone, But It Isn't the Final OneDraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Microsoft’s Neocloud Pullback Isn’t a Crack in AI DemandOklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next? Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
